Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in IgA Nephropathy (HCQIgAN)
NCT02765594Phase 4Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2016
- Primary completion
- May 2019
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hydroxychloroquine in IgA nephropathy (IgAN) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Incidence of Remission (Complete or Partial) at 24 weeks. Status: unknown.
02
Drugs
hydroxychloroquine
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT02765594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02765594.